日本Chiome Bioscience  
Chiome公司，擅长于抗体技术，称其技术平台具有"加速药物发现及推进医药开发"的潜能。该公司的"自主多元化文库（Autonomously Diversifying Library，ADLib）"系统，能够快速地产生抗体，在实验室环境下仅需短短10天时间。

Chiome is a Japan-based biotech company specialized in antibody and technology development. It has developed an innovative and unique platform technology, ADLib®system, to which right Chiome co-owns with RIKEN Institute. Since 2008, it has been engaged in joint research and the generation of antibodies with a number of leading domestic and multinational pharmaceutical and diagnostic companies. Chiome offers ADLib®system to partners under a non-exclusive license to maximize the value of the technology. By leveraging this proprietary technology Chiome Bioscience believes it can make great contributions to pharmaceutical development.